Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mogamulizumab in HTLV-1 Associated Myelopathy
NCT03191526Phase 3Terminated
- Sponsor
- Kyowa Kirin
- Start
- May 2017
- Primary completion
- Jun 2019
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in HTLV-1-associated myelopathy (HAM) comparing KW-0761 with Placebo (2 arms). Primary endpoint: Osame's Motor Disability Score at Week 24. Started May 2017; status: terminated.
02
Drugs
mogamulizumab
03
Conditions
HTLV-1-associated myelopathy (HAM)
Beyond the preview
Go deeper on NCT03191526.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03191526.